Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Ulcerative Colitis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 12
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more

Conditions: Depressive Disorder, Major
Interventions: JNJ-89495120, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more

Conditions: Hidradenitis Suppurativa, Acne Inversa
Interventions: Avacopan, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 91
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Healthy Adults, Healthy
Interventions: PF-08049820, Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: GDC-9545 Tablet, Fasted: Treatment A, GDC-9545 Capsule, Fasted: Treatment B, GDC-9545 Capsule, Fed: Treatment C; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Volunteer
Interventions: GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: BMS-986278, Rifampin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV/AIDS, HIV Prevention
Interventions: Tenofovir douche; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Sedentary Lifestyle
Interventions: Frequent sit-to-stands, Stand More; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 55 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
Interventions: Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Infant Gut Microbiome
Interventions: B. infantis EVC001, Lacto-N-tetraose (LNT); Other
Lead sponsor: Evolve BioSystems, Inc.; Industry
Eligibility: Up to 60 Days
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: Efgartigimod; Biological
Lead sponsor: M. Peter Marinkovich; Other
Eligibility: 12 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Healthy Volunteers, Alzheimer Disease
Interventions: LY3202626, Placebo (Part A, B, C), Itraconazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B); Drug · Other
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Chula Vista, California • Garden Grove, California • Los Angeles, California + 26 more

Conditions: Spinal Cord Injury
Interventions: FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment; Device · Procedure · Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Esomeprazole, Food; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Drug Abuse
Interventions: Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Autism Spectrum Disorder
Interventions: CICADAS only, PEERS + CICADAS and then no-contact, PEERS + Active Comparator and then no-contact; Other
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neoplasms
Interventions: Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Pancreatic Head Neoplasm, Delayed Gastric Emptying, Post Operative Ileus, Whipple Procedure
Interventions: pancreaticoduodenectomy; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Tenofovir Rectal Douche to Prevent HIV Transmission

Sedentary Behavior Interrupted: A Trial of Acute Effects on Biomarkers of Healthy Aging

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

The EFFECT Study: Probiotic and HMO Supplementation in Infants

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

Care Improving Cognition for ADolescents on the Autism Spectrum

Relative Bioavailability of Pimasertib in Cancer Patients

Nasogastric Decompression Following Pancreaticoduodenectomy

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study